There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Synthetic Biologics Inc (NYSE:SYN), Stemline Therapeutics Inc (NASDAQ:STML) and Quidel Corp (NASDAQ:QDEL) with bullish sentiments.
Synthetic Biologics Inc (SYN)
In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Synthetic Biologics Inc, with a price target of $38. The company’s shares closed yesterday at $3.19, close to its 52-week low of $2.55.
White commented:
“We are raising our price target to $38 up from $1, on account of the executed 1-for-35 reverse stock split. Our price target is based on probability-adjusted revenue forecasts for ribaxamase in the prevention of CDI and SYN-010 for the treatment of IBS-C.”
According to TipRanks.com, White is a 5-star analyst with an average return of 25.2% and a 54.5% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Karyopharm Therapeutics.
Synthetic Biologics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $1.
See today’s analyst top recommended stocks >>
Stemline Therapeutics Inc (STML)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Stemline Therapeutics Inc today and set a price target of $38. The company’s shares closed yesterday at $15.15.
Selvaraju said:
“Our 12-month price target is derived from a discounted cash flow-based asset value of $1.1B for 15% discount rate and 2% terminal growth rate. Probabilities of success ascribed to SL-401 and SL-701 are 90% and 45%, respectively. Investment risks include: (1) failure of drug candidates in clinical trials; (2) failure of drug candidates to secure regulatory approval; (3) failure of drug candidates to achieve commercial success due to market size, penetration rate, and/or competition; and (4) dilution risk.”
According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -3.0% and a 34.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Stemline Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $34, implying a 124.4% upside from current levels. In a report issued on August 10, Cowen & Co. also maintained a Buy rating on the stock.
.
Quidel Corp (QDEL)
Canaccord Genuity analyst Mark Massaro maintained a Buy rating on Quidel Corp today and set a price target of $78. The company’s shares closed yesterday at $70, close to its 52-week high of $73.36.
According to TipRanks.com, Massaro is a 5-star analyst with an average return of 17.4% and a 62.6% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Idexx Laboratories, Exact Sciences, and Genomic Health.
Quidel Corp has an analyst consensus of Strong Buy, with a price target consensus of $77.25, a 10.4% upside from current levels. In a report issued on August 3, Barclays also maintained a Buy rating on the stock with a $78 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
